CYPHERPUNK TECHNOLOGIES INC.
Close on Oct 19, 2026
- Market cap
- $549.88M
- P/E (TTM)
- 36.1
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | $0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.37 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | $-0.44 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | $-0.52 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | $-0.51 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | Before market open | – | $-0.46 | – |
Press releases
Announcements Cypherpunk Technologies filed with the SEC
Appoints Amanda Fabiano to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Launches World's Largest Zcash Mining Fleet
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Cypherpunk Technologies Reports Second Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
Leap Therapeutics Announces Publication of DeFianCe
Results of operations · Other events · EX-99.2 to Form 8-K
Cypherpunk Technologies Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Increa ses Treasury Holdings to 290,062.67 ZEC
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43%
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Material agreement · Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cypherpunk Technologies (formerly Leap Therapeutics)
Material agreement · Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Leap Therapeutics Presents Final Data from DeFianCe
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Announces Closing of $58.88
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces $58.88 Million Private Placement in Cash Commitments
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics Reports Updated Clinical Data
Exit or restructuring costs · Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
that involve substantial risks and uncertainties.
Exit or restructuring costs · Executive or director change · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Leap Therapeutics Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics Reports Fourth Quarter and
Results of operations · Other events · EX-99.1 to Form 8-K
Positive Updated Data from Sirexatamab Colorectal
Results of operations · Other events · EX-99.2 to Form 8-K
that involve substantial risks and uncertainties.
Results of operations · Other events · EX-99.3 to Form 8-K
Leap Therapeutics Reports Initial Clinical
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Reports Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics Announces Completion of Enrollment
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics Announces $40 Million Private
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
company presentation LEAP THERAPEUTICS April 2024
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Leap Therapeutics Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
that involve substantial risks and uncertainties.
Other events · EX-99.1 to Form 8-K
Leap Therapeutics to Present New Clinical Data
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
that involve substantial risks and uncertainties.
Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Initiation of Randomized Controlled Part B
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Announces Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Leap Therapeutics to Present Updated Data from
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Leap Therapeutics to Present Updated Data from
Other events · EX-99.1 to Form 8-K
Leap Therapeutics Announces Completion of Enrollment
Other events · EX-99.1 to Form 8-K